Stock Commentary - New York week to April 27, 2009
29 April 2009
NEW YORK: equities moved up and down during the reporting period to April 27, regaining, and holding the 8,000 level, with the Dow Jones up 2.3% over the week, encouraged by some good first-quarter results. Pharmaceutical and biotechnology issues were mixed, with 19 of those tracked rising and 17 falling. The last reporting day caused a flurry of activity among companies making influenza vaccines, due to the news of the swine flu outbreak starting in Mexico (see page 3).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
A clinical-stage biopharmaceutical company developing first-in-class programmed off-the-shelf cellular immunotherapies for cancer and autoimmune diseases.
Stock Commentary - New York week to April 27, 2009
NEW YORK: equities moved up and down during the reporting period to April 27, regaining, and holding the 8,000 level, with the Dow Jones up 2.3% over the week, encouraged by some good first-quarter results. Pharmaceutical and biotechnology issues were mixed, with 19 of those tracked rising and 17 falling. The last reporting day caused a flurry of activity among companies making influenza vaccines, due to the news of the swine flu outbreak starting in Mexico (see page 3).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Company News Directory
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
| Headless Content Management with Blaze